National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Single vs Repeated Cycle of Granulocyte Colony-Stimulating Factor (GCSF) & Darbepoetin in Early Decompensated Cirrhosis

NCT ID: NCT07131280

Last Updated: 2025-08-20

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 110 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-09-30
• Study Completion Date: 2031-12-31

Brief Summary

Chronic liver disease is a growing health concern, with limited access to liver transplants. This study addresses the urgent need for alternatives by exploring regenerative therapies, like G-CSF, to boost the liver's natural repair. The goal is to develop safe, effective, and accessible treatments for patients who cannot undergo transplant.

Detailed Description

The incidence of deaths from chronic liver diseases (CLD) and cirrhosis are rapidly increasing globally, including India. Liver transplant is the only curative option. Unfortunately, transplant is often not feasible. There is a need for nearly 100,000 liver transplants every year in India, though, only about 2,500 transplants are being done at present across the country. There is therefore, a huge unmet need of developing non-transplant options for chronic liver disease patients. In this regard emerging science of regenerative therapy holds great promises but therapeutic benefit of these therapies is limited due to lack of clinical validation.

Novelty: Cirrhosis as a result of hepatitis B and C can regress with effective antiviral therapy. Therapeutic options for patients with cryptogenic or alcoholic cirrhosis are, however, limited. With limited options for transplant. Liver failure is failure of regeneration hence, potentiating native liver repair and regeneration can serve as potential non-transplant approaches. Growth factors {like GCSF, darbepoetin (EPO) have shown survival benefits with improve liver repair and regeneration in clinical trials by us (Gastroenterology 2012, 2015, Liver Int. 2019; Hepatology 2021) and others, however the effect is transient. In the proposed National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM) we will use this novel regenerative medicine approaches GCSF therapy (for management of chronic liver failure) to develop safe and effective regenerative therapy clinical protocol for transplant free management of liver failure in cirrhosis. Using integrated cellular, molecular and functional analysis we will also establish their mechanism of action and identify biomarker to access therapeutic response.

Conditions

Decompensated Cirrhosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Three cycles of GCSF+ darbepoetin and standard medical treatment

Patient randomize for Three cycle of GCSF+ darbepoetin together with standard medical treatment, G-CSF will be given at a dose of 5 μg/kg s/c at days 1, 2, 3, 4, 5 and then every third and 7th day till day 30 based on hematological response and darbepoetin will be given s/c at dose of 40mcg once a week (total 4 doses) for 1 month. Second cycle of GCSF+ darbepoetin will be given after 1 month of completion of first cycle that is at month 3 and third cycle will be given 1 month after completion of 2nd cycle that is at 5th month. All patients will receive the standard medical treatment.

Group Type: EXPERIMENTAL

Gcsf

Intervention Type: DRUG

G-CSF will be given at a dose of 5 μg/kg s/c at days 1, 2, 3, 4, 5 and then every third and 7th day till day 30

Darbepoetin

Intervention Type: DRUG

Darbepoetin will be given s/c at dose of 40mcg once a week for 1 month

Standard Medical Treatment

Intervention Type: OTHER

Standard Medical Treatment

Single cycle of GCSF+ darbepoetin and standard medical treatment

Patient randomize for Single cycle of GCSF+ darbepoetin together with standard medical treatment, G-CSF will be given at a dose of 5 μg/kg s/c at days 1, 2, 3, 4, 5 and then every third and 7th day till day 30 based on hematological response and darbepoetin will be given s/c at dose of 40mcg once a week (total 4 doses) for 1 month. All patients will receive the standard medical treatment.

Group Type: ACTIVE_COMPARATOR

Gcsf

Intervention Type: DRUG

G-CSF will be given at a dose of 5 μg/kg s/c at days 1, 2, 3, 4, 5 and then every third and 7th day till day 30

Darbepoetin

Intervention Type: DRUG

Darbepoetin will be given s/c at dose of 40mcg once a week for 1 month

Standard Medical Treatment

Intervention Type: OTHER

Standard Medical Treatment

Interventions

Gcsf

G-CSF will be given at a dose of 5 μg/kg s/c at days 1, 2, 3, 4, 5 and then every third and 7th day till day 30

Intervention Type: DRUG

Darbepoetin

Darbepoetin will be given s/c at dose of 40mcg once a week for 1 month

Intervention Type: DRUG

Standard Medical Treatment

Standard Medical Treatment

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Early decompensated cirrhosis patients with MELD <16

Exclusion Criteria

• Patients with age less than 18 years or more than 65 years
• Patients with Grade III ascites
• CHILD C cirrhosis
• Patients with a known focus of sepsis; spontaneous Bacterial Peritonitis (SBP)
• variceal bleeding in past 3months
• Hepatocellular Carcinoma (HCC) or other malignancy
• Acute Kidney Injury (AKI) with serum Creatinine >1.5 mg/ dl, multi-organ failure, grade 3 or 4 Hepatic Encephalopathy (HE),
• HIV seropositivity
• Medically uncontrolled essential hypertension
• Pregnancy
• Viral etiology of liver disease
• Co-existent Hepatitis B, Hepatitis C, HIV
• Chronic kidney disease
• Lack of informed consent

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Indian Council of Medical Research

OTHER_GOV

Sponsor Role: collaborator

Institute of Liver and Biliary Sciences, India

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Dr. Shiv Kumar Sarin, DM

Role: PRINCIPAL_INVESTIGATOR

Institute of Liver & Biliary Sciences

Locations

Institute of Liver & Biliary Sciences

New Delhi, , India

Countries

India

Central Contacts

Dr. Anupam Kumar, PhD

Role: CONTACT

dr.anupamkumar.ilbs@gmail.com

01146300000

Fagun Sharma, M.Sc.

Role: CONTACT

fagun.30sharma@gmail.com

01146300000

Facility Contacts

Dr. Anupam Kumar, PhD

Role: primary

dr.anupamkumar.ilbs@gmail.com

01146300000

Other Identifiers

ILBS-Cirrhosis-75

Identifier Type: -

Identifier Source: org_study_id